Bioscience is a technology company.
Bioscience has raised $16.0M across 1 funding round.
Bioscience has raised $16.0M in total across 1 funding round.
Bioscience, as a technology company, typically refers to firms operating within the biotechnology and life sciences sectors, developing innovative products or platforms that advance scientific discovery, healthcare, or industrial applications. Such companies often build specialized products like molecular diagnostics, synthetic DNA, or biologic medicines, serving healthcare providers, researchers, and pharmaceutical companies. They solve critical problems such as disease diagnosis, treatment personalization, drug development acceleration, or safety testing. Many bioscience companies demonstrate strong growth momentum driven by cutting-edge technology adoption and expanding market needs for precision medicine and biotechnological innovation[1][2][3][4].
Bioscience companies often originate from scientific founders with backgrounds in biology, chemistry, or medicine who identify unmet needs in healthcare or research. For example, Castle Biosciences was founded to improve disease management through advanced molecular diagnostics, leveraging genomic profiling to inform treatment decisions[2]. Twist Bioscience emerged from a vision to revolutionize DNA synthesis using proprietary semiconductor technology, enabling high-throughput and cost-effective gene synthesis[3]. These companies typically gain early traction by validating their technologies through clinical studies or partnerships, establishing credibility and market presence.
Bioscience companies ride the wave of precision medicine, genomics, and synthetic biology trends, which are transforming healthcare and industrial biotech. The timing is critical as advances in computational biology, AI, and high-throughput technologies converge to enable personalized treatments and faster drug development. Market forces such as increasing chronic disease prevalence, demand for safer biologics, and regulatory support for innovative diagnostics favor growth. These companies influence the broader ecosystem by setting new standards in molecular diagnostics, enabling synthetic biology applications, and driving the integration of digital tools in life sciences research[1][2][3][5].
Looking ahead, bioscience companies are poised to expand their impact by leveraging AI-driven analytics, expanding into new therapeutic areas, and scaling manufacturing innovations to reduce costs. Trends like gene editing, cell therapies, and environmental biotech applications will shape their evolution. Their influence will likely grow as they enable more precise, accessible, and sustainable healthcare solutions, continuing to transform disease management and biotechnological research. This trajectory ties back to their foundational mission of advancing science to improve human health and quality of life[1][2][3][6].
Bioscience has raised $16.0M in total across 1 funding round.
Bioscience's investors include Qiming Venture Partners.
Bioscience has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series C in October 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2017 | $16.0M Series C | Qiming Venture Partners |